Closing the Gap: Advancing Precision Oncology Through Education and Collaboration
How top-to-bottom collaboration can alleviate hurdles and help increase equitable access to the most effective treatments for all cancer patients.
FDA green-lights second RET inhibitor, this time from Blueprint Medicines
The drug, Gavreto, or pralsetinib, won accelerated approval for RET fusion-positive non-small cell lung cancer, with or without prior therapy, while the FDA accepted the company's approval application for the drug in two types of thyroid cancer. The approval follows the May nod for Eli Lilly's Retevmo for all three indications.
Health Executives on Digital Transformation in Healthcare
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Amgen’s drug targeting ‘undruggable’ protein shines at lung cancer conference
Amgen presented data for the KRAS G12C inhibitor AMG 510 at the World Conference on Lung Cancer in Barcelona, showing a 54 percent response rate among patients receiving the pivotal study dose.
Lilly’s biomarker-driven drug shows strong, durable response rates in lung cancer patients
Analysts nevertheless wrote that with each data update, Lilly's RET inhibitor LOXO-292 (selpercatinib) appears less differentiated on efficacy as well as tolerability from Blueprint Medicines' BLU-667 (pralsetinib).
AstraZeneca immunotherapy combo flunks another lung cancer study
The company said Wednesday that the pairing of PD-L1 inhibitor Imfinzi and CTLA-4 inhibitor tremelimumab did not prolong overall survival in previously untreated metastatic non-small cell lung cancer. The Phase III results are the latest in a string of failures for the combination.
AstraZeneca formally removes two failed Phase III studies of cancer drug Imfinzi
The studies - in lung and head and neck cancers - produced negative results late last year. Several Phase I Imfinzi and tremelimumab studies were also removed, but others were added to the company's pipeline.
presented by
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
AstraZeneca looks to salvage data from negative Imfinzi lung cancer study
The company pointed to better survival numbers in patients with high tumor mutational burden, in a presentation at the ESMO immuno-oncology congress in Geneva.
AstraZeneca lung cancer immunotherapy trial fails, dealing blow to company
Data from the Phase III MYSTIC study showed Imfinzi and tremelimumab did not extend survival in first-line NSCLC. AstraZeneca's shares were down on the news.